Last reviewed · How we verify

Opdualag — Competitive Intelligence Brief

Opdualag (Opdualag) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Lymphocyte activation gene 3 protein Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Opdualag (Opdualag) — Australian & New Zealand Children's Haematology/Oncology Group.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Opdualag TARGET Opdualag Australian & New Zealand Children's Haematology/Oncology Group marketed Lymphocyte activation gene 3 protein
OPDUALAG RELATLIMAB-RMBW BRISTOL MYERS SQUIBB marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Lymphocyte activation gene 3 protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Opdualag — Competitive Intelligence Brief. https://druglandscape.com/ci/opdualag. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: